IGC Launches Phytocannabinoid Development Committee to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
84
IGC Launches Phytocannabinoid Development Committee to Secure Preclinical Initiatives for IGC-501, IGC-502 and IGC-504

BETHESDA, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) announces today that its Phytocannabinoid Development Committee has started its review of international medical facilities as per its mandate to commence preclinical trials in support of IGC’s patent portfolio.  The Committee has a particular focus on Israel, among others, given the Country’s current cannabis research policies and depth of qualified healthcare organizations.

During the preclinical phase, each compound will undergo toxicity assessment and development of their pharmacological profile. It is anticipated that these multi-week initiatives will allow for the collection of important data related to safety, iterative testing and feasibility.  

IGC-501 is indicated for neuropathic pain. The pain market represents a significant component of the healthcare system and The Journal of Pain in September 2012 reported that the annual estimated national cost of pain ranges from $560 billion to $635 billion. Additionally, The American Pain Society recommends that pain be made more visible and be categorized as the fifth vital sign.

IGC-502 is indicated for seizures. Approximately 50 million people worldwide are affected by Epilepsy (Sanders, 2003). Epilepsy is thought to be due to multiple factors that include Sodium, Potassium, GABA (gamma amino butyric acid) and NMDA (N-Methyl-d-aspartate). It is believed that to maximally control Epilepsy, modulation of one or more of these receptors is required and that mono therapy is adequate in up to 25% of patients.

IGC-504 is indicated for eating disorders. Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. In the U.S. it is estimated that a population of approximately 1.3 million are experiencing Cachexia associated with Cancer, Multiple Sclerosis, Parkinson’s disease, HIV/AIDS and other progressive illnesses. Cancer induced Anorexia Cachexia is responsible for about 20% of all cancer deaths.

About IGC

In the United States, we develop phytocannabinoid-based therapies. IGC has assembled a portfolio of patent filings that encompasses the indications of Pain, Medical Refractory Epilepsy and Cachexia using cannabinoids. We are based in Bethesda, Maryland.

Our website: www.igcinc.us . Twitter @IGCIR Facebook.com/IGCIR/

Forward-looking Statements Some of the statements contained in this press release that are not historical facts constitute forward-looking statements under the federal securities laws. Forward-looking statements can be identified by the use of the words "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "intends," "potential," "proposed" or the negative of those terms. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond IGC's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in IGC's business and acquisition and diversification strategy, competitive environment, infrastructure demands, and governmental, regulatory, political, economic, legal and social conditions in, among other places, China and India. Except as required by federal securities laws, IGC undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information or future events, or otherwise. Other factors and risks that could cause or contribute to actual results differing materially from such forward-looking statements have been discussed in greater detail in IGC's Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.

Contact Info: Claudia Grimaldi 301-983-0998

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading